Who we are
WHO WE ARE
Purpose and Objectives
OUR VALUES
STRUCTURE
OUR MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
JOB OPPORTUNITIES
Key topics
COVID-19
Access
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
Factsheets
Infographics
Reports
Policy
Videos
Podcast – Conversations on EU Pharma
Newsroom
Press releases
In the news
Press kit
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Environment of value added medicines in Europe
Definition
THERAPEUTIC AREAS
Q&A
What’s new
Environment of value added medicines in Europe
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Value Added Medicines award 2019
QUOTES
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Newsroom
Filters:
Biosimilar medicines
x
press-releases
x
2022
x
News about
By type
In the news
Press releases
Twitter
Tweets
Videos
Photos
Billions more euros to re-invest in better healthcare thanks to biosimilar medicines
13 December 2022
Open
Pharmaceutical legislation reforms must support equitable access to medicine in Central and Eastern Europe and security of medicines supplies
16 November 2022
Open
Proposals on wastewater treatment will jeopardise patient access to medicines without helping green transition
26 October 2022
Open
Rapid policy action needed to protect patient access to essential medicines as inflation bites
12 October 2022
Open
EU pharmaceutical legislation reform critical to sustain biosimilar medicines competition for the future
6 October 2022
Open
Updated Guide to empower nurses managing patients on biological therapies
3 October 2022
Open
EMA/HMA share definitive EU-wide position on biosimilar medicines interchangeability
19 September 2022
Open
Medicines for Europe warns strongly against energy rationing for medicines production
20 July 2022
Open
The Supplementary Protection Certificate (SPC) manufacturing waiver becomes operational!
1 July 2022
Open
The off-patent medicines industry is a vital part of the solution for healthcare resilience
30 June 2022
Open
Posts navigation
1
2
Subscribe to our newsletter
Medicines For Europe
Who we are
WHO WE ARE
Purpose and Objectives
OUR VALUES
STRUCTURE
OUR MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
JOB OPPORTUNITIES
Key topics
COVID-19
Access
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
Factsheets
Infographics
Reports
Policy
Videos
Podcast – Conversations on EU Pharma
Newsroom
Press releases
In the news
Press kit
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Tweet
Tweet
Tweet
LinkedIn